News and insights
223 81 Lund, Sverige
+46 46-15 21 00
©Copyright 2023 CLS AB. All rights reserved.
CLS’ management team has extensive experience in product and business development of medtech products, as well as in cancer care, regulatory work and international marketing.
Dan J. Mogren
CEO since 2022
CLS employee since 2014, acting CEO 2020-2022
Dan Mogren has 20 years of experience from leading positions in business and product development, marketing and sales, as well as 15 years of experience in international marketing of medical devices. Dan Mogren has founded and developed several companies in the medical device field.
Holdings in CLS: 126 384 Class B shares and 63 192 warrants plus 126 384 Class B shares and 37 683 warrants via Medinovus AB.
Chief Technology Officer since 2022, previously Technical Manager
Cristina Pantaleone, MSc Physics Engineering, has experience in the development of medical devices, expertise in light-tissue interaction and a deep understanding of CLS’s technology and product range.
Holdings in CLS: 20 799 Class B shares and 4 020 warrants.
Chief Financial Officer since 2022
Rolf Bornschein has more than 15 years of experience in finance with listed as well PE-owned companies. He started his career as an auditor with Ernst & Young. Since then he has had several leadership positions in finance, but also business development and commercialization, most recently with Atos Medical.
Holdings in CLS: 300 000 Class B shares and 150 000 warrants.
VP Regulatory Affairs & Quality Assurance since 2021
Anders Qvarlander has extensive experience from leading positions within market expansion, regulatory product approvals and quality assurance of medical devices from previous employments at Baxter, Arjo and Mediplast, among others.
Holdings in CLS: 30 000 Class B shares and 15 000 warrants.
VP Marketing since 2021
Liselotte Nilsson, MSc Molecular Biology, has many years of experience in international marketing from the medical device industry, including commercial and scientific marketing communication and product management from, among others, ProstaLund, Phase Holographic Imaging and Svar Life Science.
Holdings in CLS: 20 000 Class B shares and 10 000 warrants.
VP Medical Affairs since 2021
Hoda Tawfik, PhD University of Cairo, Faculty of Pharmacy, Dept. of Pharmacology and Toxicology, has many years of experience in research work and clinical development from the academic field as well as in international companies such as Medigene and Magforce Nanomedicine.
Holdings in CLS: No shares, no warrants.
EVP Operations since 2023
Jimmy Johansson, MSc Electrical Engineering, has extensive experience from medical device and healthcare sector. Jimmy Johansson has previously held several leading positions in business and product development, as well as quality assurance of medical devices, at various companies.
Holdings in CLS: 3535 Class B shares plus 178 570 Class B shares via Medtech Öresund AB.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region